Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu M, Robinson P, Yau C, Wallace A, Chien A, Stringer-Reasor E, Nanda R, Yee D, Albain K, Boughey J, Han H, Elias A, Kalinsky K, Clark A, Kemmer K, Isaacs C, Lang J, Lu J, Sanft T, DeMichele A, Hylton N, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Haugen P, Wilson A, Singhrao R, Asare S, Sanil A, Berry D, Esserman L. Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2020, 80: p3-09-02-p3-09-02. DOI: 10.1158/1538-7445.sabcs19-p3-09-02.Peer-Reviewed Original ResearchPathological complete responseHER2 negative breast cancerI-SPY 2 TRIALWeeks of paclitaxelNegative breast cancerNeoadjuvant therapyBreast cancerHR-/HER2High-risk stage II/III breast cancerImmune-related adverse eventsPathologic complete response rateRandomized phase 2 trialStage II/III breast cancerHormone-receptorI-SPYEvaluate novel agentsGrade 3 colitisGrade 3 pneumonitisGrade 3 transaminitisPhase 2 trialPhase 3 trialBayesian predictive probability of successNeoadjuvant trialsWeekly paclitaxelComplete responseAbstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI
Li W, Onishi N, Newitt D, Harnish R, Jones E, Wilmes L, Gibbs J, Price E, Joe B, Chien A, Berry D, Boughey J, Albain K, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yee D, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Yau C, Asare S, DeMichele A, Goudreau S, Abe H, Sheth D, Wolverton D, Fountain K, Ha R, Wynn R, Crane E, Dillis C, Kuritza T, Morley K, Nelson M, Church A, Niell B, Drukteinis J, Oh K, Jafarian N, Brandt K, Choudhery S, Bang D, Mullins C, Woodard S, Zamora K, Ojeda-Fornier H, Eghedari M, Sheth P, Hovanessian-Larsen L, Rosen M, McDonald E, Spektor M, Giurescu M, Newell M, Cohen M, Berman E, Lehman C, Smith W, Fitzpatrick K, Borders M, Yang W, Dogan B, Esserman L, Hylton N. Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI. Cancer Research 2020, 80: p6-02-01-p6-02-01. DOI: 10.1158/1538-7445.sabcs19-p6-02-01.Peer-Reviewed Original ResearchEffect of background parenchymal enhancementFunctional tumor volumeBackground parenchymal enhancementLower background parenchymal enhancementNeoadjuvant chemotherapyTumor volumeParenchymal enhancementDynamic contrast-enhancedHR-/HER2Treatment time pointsContralateral breastPatient cohortTime pointsHigher background parenchymal enhancementI-SPY 2 TRIALWeeks of neoadjuvant chemotherapyLocally advanced breast cancerMRI examsHormone receptorsHR-/HER2- subtypeMR tumor volumesPrediction of pCRNeoadjuvant chemotherapy regimensEnhancement thresholdHR-/HER2+